London Bridge 2 PCC ("LB2")

A risk transformation vehicle for institutional investors to access the Lloyd's market

Executive Summary

- Lloyd's is the world's premier marketplace for insurance and reinsurance, made up of over 50 leading insurance companies underwriting global specialty (re)insurance risks through approx.100 syndicates, generating over £46.7bn in gross written premium*
- Lloyd's is a great place for institutional investors to gain access to global (re)insurance risk. Its unique structure and leading market presence provides investors with the additional comfort of the principles-based oversight by The Corporation of Lloyd's
- The London Bridge risk transformation platform, which was sponsored by Lloyd's as part of its "Future at Lloyd's" strategy, is an efficient way for
 market participants to either:
 - a) raise solvency capital to support underwriting at Lloyd's and/or
 - b) transfer specific risks to the capital markets as part of a syndicates' risk management strategy
- London Bridge has to date issued over US\$750mn in securities to institutional investors, across 13 cells, including its first 144A catastrophe bond transaction
- This transaction success provides a valuable roadmap for other market participants to follow, as Lloyd's seeks to improve access to the market for institutional investors, to provide a more meaningful and diversified source of capital for members and syndicates in support of the profitable growth ambition of the market



Good progress on market access & process improvements


- Development and publication of "An Introduction to Lloyd's" guide for institutional investors, covering an overview of the market, its participants, and the important role of The Corporation of Lloyd's
- Successful execution of multiple Member Funds At Lloyd's ("FAL") Reinsurance transactions and the first 144A cat bond transaction for a syndicate, which provides a valuable roadmap for other potential market participants
- Variation to the LB2 regulatory permissions to (a) streamline the Member FAL Reinsurance structure; and (b) facilitate the issuance of 144A cat bonds for multiple cedants, in the same group, and the use of New York as the governing law for the principal transaction documentation
- Provision of access to the Member Modeller for the leading reinsurance brokers/advisors involved in structuring and placing of Member FAL Reinsurance transactions
- Development and implementation of a fast-track route to review Corporate Member applications, including the KYC process, with the successful deployment of the Onboard tool by RiskScreen
- Enhanced flexibility of liquidity options for Member FAL investors through the Reinsurance to Close (RITC); Quarterly Corridor Test (QCT); and Open Year Profit release mechanisms
- Continue to advocate the other potential uses for the London Bridge platform, including:
 - a) Member FAL Reinsurance (on an Excess of Loss basis)
 - b) Syndicate Reinsurance 144A Cat Bond, using an industry loss index structure, and
 - c) Syndicate Reinsurance Quota-share Sidecar structure

LONDON BRIDGE 2 PCC LIMITED

What is London Bridge 2 PCC Limited?

London Bridge 2 PCC Limited ("LB2") is the second Multi-arrangement Insurance Special Purpose Vehicle (a "transformer" vehicle), sponsored by Lloyd's, which transforms (re)insurance risk underwritten at Lloyd's business into investible securities (equity or debt instruments) offered to institutional investors.

Participation in the underwriting of risks at Lloyd's can be structured in multiple ways, with several unique aspects that can make deploying capital flexible, efficient and cost effective, as LB2 has a set of regulatory permissions that enables it to execute at speed.



Reinsurance Risk Transformation

- LB2 is an onshore protected cell company incorporated in England under the Risk Transformation Regulations 2017.
- Authorised and supervised by the PRA and FCA ("UK Regulators") as a multi-arrangement insurance special purpose vehicle.
- LB2 is licensed to reinsure business underwritten at Lloyd's and issue securities to fully fund the obligations under the reinsurance agreements.
- LB2 is tax transparent and is not subject to withholding or income tax on its transactions.

Protected Cell Structure

- Each transaction will be entered into through a segregated protected cell that will also issue the applicable securities. The liabilities of each cell are ringfenced for insolvency purposes.
- Each transaction entered into will be:
 - on a limited recourse basis with the aggregate liability limited to the value of the cell's funded assets, and
 - subject to priority of payments with investors' rights subordinated to the reinsured.


Enhanced Regulatory Permissions

- The regulatory permissions for LB2 enables it to offer a broad range of risk transfer options to both Corporate Members and Syndicates at Lloyd's.
- The Board of LB2 has the authority to enter into these transactions without further regulatory approval, provided that the key transaction documentation include certain Mandatory Terms that comply with the Risk Transformation Regulations 2017 and certain articles of the Commission of Delegated Regulation (EU) 2015.
- LB2 need only share transaction Term Sheets 5 days prior to completion and confirm risk being bound 5 days after.



How is London Bridge 2 Governed

An independent board, with management services outsourced to an ILS market leader



Governance summary

- London Bridge 2 is an independently owned limited company, owned by an orphan trust.
- The Board of Directors have appointed:
 - Artex Capital Solutions to provide insurance management services
 - Intertrust to provide corporate secretarial services
- The independent Board is made up of Directors from Lloyd's, Artex and Intertrust
- The Board has delegated authority for underwriting decisions to an Underwriting Committee
- The Underwriting Committee approves transactions and Cell creation on an ongoing basis, with Board ratification on a quarterly basis
- The Board operates within a set of governance and policy standards, approved by the UK Regulators and consistent with the risk transformation nature of the company.

6

What is the role of the Artex, the LB2 Insurance Manager?

Artex Capital Solutions has unrivalled experience in managing large ILS platforms



Principal point of access for LB2

- Promote LB2 capabilities to market participants, via various media and initiatives.
- Acting as the 'go-to' subject matter expert for all transaction enquiries.
- Advise potential users on the capabilities of LB2 to achieve their desired risk transfer objectives.



Management of individual Cells

- Deliver Cell level management, including entering into reinsurance transactions.
- Liaison with Members and Syndicates, Investors
 and other service providers, on potential
 transaction structures.
- Provides regular reporting and valuation services (as required) to investors.



Management of the Core LB2 company

- Undertakes day-today administration of the PCC's operations, including accounting and regulatory reporting.
- Provides regular reports to LB2 board.
- Underwriting sub-committee has been established to provide efficient transaction review and prompt decision making

Ed Saul

Vice President
Artex Capital Solutions
67 Lombard Street | London | EC3V 9BQ
m: +44 7717 514109
www.artexrisk.com | ed saul@artexrisk.com



LB2 TRANSACTION STRUCTURES & CASE STUDIES


Potential LB2 Transaction Structures

Ability to reinsure at either Corporate Member or Lloyd's Syndicate level

Member Reinsurance - "FAL"



Syndicate Reinsurance – "Collateralised Re"




Transaction Options	
Types of Member Reinsurance	Whole account quota share (up to 100%)Excess of Loss
Capital requirement	 SII based assessment for Funds at Lloyd's (FAL) Diversifications benefits established via Member modeler.
*Types of Security to be issued	Preference SharesDebt
Duration of Arrangements	 Single Year of Account Multiple Years of Account (subject to annual endorsement)
Investment Policy	Eligible assets under Lloyd's standard strategic asset allocation (does not include LoCs)

Transaction Options	
Types of Syndicate Reinsurance	 Whole account or variable quota share Excess of Loss (inc. cat bonds) No line of business restriction
Capital requirement	 Fund to aggregate limit of liability QS agreement limit of liability is likely to be determined at a point on an Aggregate EP curves
*Types of Security to be issued	Preference SharesDebt
Duration of Arrangements	 Defined risk period, most likely in accordance with existing annual reinsurance arrangements
Investment Policy	 Core eligible assets under Lloyd's standard strategic asset allocation (mainly cash or high quality, short dated government securities)



Transaction Structure - Member Funds at Lloyd's Reinsurance




Classification: Unclassified

10



Transaction Cashflows - Member Funds at Lloyd's Reinsurance



Classification: Unclassified

Case Study: Member FAL Reinsurance

OTTP raises capital to support the 2021 underwriting plan of multiple syndicates

November 2021

LONDON BRIDGE Risk PCC LIMITED acting through one protected cell.

US\$ Undisclosed



Private Placement of Non-Voting, Redeemable Preference Shares Ontario Teachers' Pension Plan (OTTP) became the debut user of the London Bridge Risk PCC ("LB1") risk transformation vehicle.

OTTP invested a substantial undisclosed sum via a single corporate Member supporting multiple syndicates in the Lloyd's market including: Beat Syndicate 1416, Beazley Syndicate 5623 and CFC Syndicate 1988.

The reinsurance agreement with the corporate Member was a whole-account quota share agreement, with the proceeds being lodged as Funds-at-Lloyd's ("FAL"), under the Lloyd's Deposit Trust Fund.

Adrian Cox, CEO of Beazley Group, said: "Beazley is pleased to see the successful launch of the first LBR PCC acting as a transformer for institutional capital to access one of our most innovative underwriting portfolios. As those portfolios continue to grow over the coming years, Beazley hopes to see further users of the new UK ILS infrastructure benefiting from low cost, efficient access to the group's underwriting expertise."

Case Study: Member FAL Reinsurance

Ariel Re raises \$172mn to support the 2023 underwriting plan for Syndicate 1910

February 2023

LONDON BRIDGE 2 PCC LIMITED acting on behalf of 4 protected cells.

US\$171.5 million



Private Placement of Non-Voting, Redeemable Preference Shares

Financial Advisor:

Howden Tiger Capital Markets & Advisory

Ariel Re became the debut user of the recently established London Bridge 2 PCC ("LB2") risk transformation vehicle.

LB2, through 4 separate protected cells, issued non-voting redeemable preference shares with an aggregate notional value of US\$171.5 million, to generate funds for 4 separate corporate Members that participate in the 2023 underwriting of Syndicate 1910.

The reinsurance agreements with the respective corporate Members were whole-account quota share agreements, with the proceeds of the securities issued being lodged as Funds-at-Lloyd's ("FAL"), under the Lloyd's Deposit Trust Fund.


The qualified investors that purchased the preference shares were all new investors in the Lloyd's market, including U.S. private equity funds and a U.S. alternative asset manager.

Ryan Mather (CEO of Ariel Re) commented "We strongly support Lloyd's effective efforts to make it simpler and more efficient to invest in Lloyd's, and we are delighted that part of our new funding is the first successful example of investors coming to Lloyd's via the innovative LB2 structure."

Since the initial transaction Ariel not only introduced further investors via LB2 during 2023, but also expanded the level of capital support for the 2024 year of account.



Transaction Structure - Syndicate Reinsurance (144A Cat Bond)




14

Classification: Unclassified



Transaction Cashflows - Syndicate Reinsurance (144A Cat Bond)



15

Classification: Unclassified

Case Study: Syndicate Reinsurance (144A Property Cat Bond)

Beazley sponsors its first ever 144A property catastrophe bond via LB2

December 2023

LONDON BRIDGE 2 PCC LIMITED

acting through its protected cell Fuchsia 2023-1

Principal At-Risk Variable Rate Notes due April 6, 2027 US\$100 million



Financial Advisor:

AON Securities

Beazley sponsored a catastrophe bond via the London Bridge 2 PCC ("LB2") risk transformation vehicle. This is Beazley's **debut 144A natural catastrophe bond**, and the **first excess-of-loss cat bond issuance** through the London Bridge 2 PCC structure. London Bridge 2 PCC Limited issued a single, \$100 million tranche of Series 2023-1 notes via a protected cell named Fuchsia 2023-1.

The Fuchsia 2023-1 notes were sold to institutional investors and the proceeds used to collateralise a reinsurance agreement between the cell of London Bridge 2 PCC and Beazley. The principal transaction documentation were governed by New York law, with the mandatory conditions governed by the laws of England and Wales.

The protection provides indemnity coverage to Beazley against losses from named storm and earthquake events affecting the United States, Canada and certain parts of the Caribbean. This multi-year excess of loss reinsurance coverage protects multiple Beazley underwriting entities, including its syndicates at Lloyd's, its US E&S insurer, and Irish insurer.

Adrian Cox, CEO of Beazley plc, commented: "Beazley is delighted to be sponsoring the first 144A property catastrophe bond utilising the London Bridge platform. We were impressed with the smooth and efficient way that an ILS transaction can be issued out of the UK market."

LLOYD'S

Disclaimer

This Presentation has been prepared by Lloyd's (a) solely to provide information about Lloyd's and the business of the Lloyd's market and (b) for general information purposes only.

This Presentation is not an offering of securities or other financial products for sale or other investment. No recipient of this Presentation should construe the information contained herein or in any prior or subsequent communication as a recommendation that such recipient invest in securities or other financial products. The information contained in this Presentation is in summary form for convenience of presentation. It is not complete, and it should not be relied upon as such. Nothing contained herein should be relied upon as a promise or representation as to past or future performance. In addition, past performance is not necessarily indicative of future performance.

The Presentation is directed at, and is solely for the use of, persons with professional experience in investments ("professional investors") and any security or financial product referred to in this Presentation is only available to professional investors. This Presentation is provided on the basis that, as a professional investor, you understand and accept the inherent limitations of this Presentation.

While care has been taken in the preparation of this Presentation, no representation or warranty, express or implied, is made or given on behalf of Lloyd's or any other person or entity as to the accuracy, completeness or fairness of the information contained in this Presentation or any other material referred to herein. Lloyd's accepts no responsibility or liability for any loss or damage of any kind occasioned to any person or entity as a result of acting or refraining from acting as a result of, or in reliance on, any statement, fact, figure or expression of opinion or belief contained in this Presentation. This Presentation does not constitute advice of any kind.

No money or other consideration is being solicited by reason of the delivery of this Presentation. Any indication of interest to participate in the Lloyd's market or to invest in any participant in the Lloyd's market in response to this Presentation involves no obligation or commitment of any kind.

United States

Certain of the statements included in this Presentation may constitute forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "anticipates," "includes," "plans," "assumes," "estimates," "projects," "intends," "should," "will," "shall" or variations of such words are generally part of forward-looking statements. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties, and there are certain important factors that could cause actual results to differ, possibly materially, from expectations or estimates reflected in such forward-looking statements Forward-looking statements cannot be verified solely by reference to historical facts. Because they are based on assumptions about future events or circumstances, forward-looking statements can only illustrate hypothetical results given those assumptions. Assumptions may be based upon historical experience, but there is no assurance that future performance will be consistent with historical experience. Actual events or circumstances are unlikely to be consistent with, and may differ materially from, assumed events or circumstances (including historical experience).

In order to be eligible to receive and review this Presentation, you must be (a) a "qualified institutional buyer" within the meaning of Rule 144A under the US Securities Act of 1933, as amended (the "Securities Act"), (b) an "accredited investor" within the meaning given to such term in paragraph (1), (2), (3), (7), (8), (9), (12) or (13) of Rule 501(a) under the Securities Act that is also a "qualified purchaser" within the meaning of Section 3(c)(7) of the US Investment Company Act of 1940, as amended (the "Investment Company Act"), or (c) not a "U.S. person" within the meaning of Regulation S under the Securities Act.

LLOYD'S